Day: September 24, 2025

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO, Sept. 24, 2025 (GLOBE NEWSWIRE) — SOL Strategies Inc. (CSE:HODL) (“SOL Strategies” or the “Company”), is pleased to announce that it has agreed to increase the size of its previously announced private placement of up to C$25,000,000 of units of the Company (the “Units”) pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and Coordinated Blanket Order 45-935 of the Canadian Securities Administrators (the “LIFE Offering”). The upsized LIFE Offering will consist of 4,380,000 Units of the Company at a price of $6.85 per Unit (the “Offering Price”) for gross proceeds of $30,003,000....

DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, is positioning itself at the forefront of a new frontier in sportswear innovation as it prepares to reconvene its recombinant spider silk production program. Kraig Labs plans on delivering the first spider silk fiber samples to two of the sports companies it announced earlier this year. These deliveries will mark a pivotal moment in KBLB’s evolution from R&D into potential revenue-generating partnerships. 24/7 Market News does not know the initial target applications, but the conventual wisdom is that spider silk fibers,...

ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it will present at the Emerging Growth Conference 86 on September 25, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investment community the opportunity to engage directly with Vivani President and CEO Adam Mendelsohn, Ph.D. Dr. Mendelsohn will provide an overview of the Company and, time permitting, open the floor to questions afterward. Please submit your questions in advance to: Questions@EmergingGrowth.com. Vivani will present for 30 minutes starting...

All figures expressed in USD unless noted otherwise. DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) — Vox Royalty Corp. (TSX: VOXR) (NASDAQ: VOXR) (“Vox” or the “Company”), a returns focused mining royalty and streaming company, is pleased to confirm the pricing of its previously announced public offering (the “Offering”) of common shares of the Company (“Common Shares”) at an offering price of $3.70 per share (the “Offering Price”). The Offering is expected to close on or about September 26, 2025, subject to customary closing conditions and the receipt of regulatory approvals, including the approval of the Toronto Stock Exchange (“TSX”) and the Nasdaq Capital Markets. In connection with the Offering, Vox entered into an underwriting agreement, dated September 24, 2025 (the “Underwriting Agreement”) with each of BMO Capital Markets, Cantor...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 6 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated data presentations including new six-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, where we and our Ex-U.S. partner, Neuraxpharm, are exhibiting. Links to each presentation as well as highlights from the...

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable safety profile, consistent with observations from the first 100 patients treated with KYV-1011 Encouraging early data of KYV-101 in multiple sclerosis highlights broader potential within neuroimmunology autoimmune diseases EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced updated data from Phase 1 investigator-initiated trials (IITs) of KYV-101 in the treatment of progressive multiple sclerosis (MS) to be presented at...

VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the “Offering”) of 14,636,363 common shares of the Company (the “Common Shares”), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$5.50 per Common Share for gross proceeds of approximately US$80.5 million, before deducting the underwriting commissions and estimated expenses incurred in connection...

Annual Client Satisfaction Survey Reflects the Views of Senior HR Decision Makers OLD GREENWICH, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) (“Star” or the “Company”), a diversified holding company, announced today that its wholly owned subsidiary, Hudson Talent Solutions (HTS) has ranked among HRO Today magazine’s Baker’s Dozen list of top enterprise recruitment process outsourcing (RPO) providers for the 17th consecutive year. This year, HTS not only maintained its place among the world’s best but also advanced up the rankings, signaling strong momentum in its RPO delivery and client satisfaction. HTS achieved a ranking of #5, in the “Overall Enterprise RPO Leaders” category, which is the highest ranking for HTS over the last 17 years. Of note, HTS ranked #6 in the same category...

Taren Point, Australia, Sept. 24, 2025 (GLOBE NEWSWIRE) — Fitell Corporation (NASDAQ: FTEL) (“FTEL” or the “Company”), today announced its initial acquisition of 46,144 Solana (SOL) for approximately $10 million, marking the first strategic purchase under the Company’s previously announced Solana treasury initiative. “This initial $10 million purchase, in one day following our $100 million financing announcement, manifests FTEL’s execution and commitment to our newly launched Solana treasury strategy” said Sam Lu, Chief Executive Officer of FTEL. “With committed institutional support, we look forward to expanding our SOL position, in addition to growing staking revenue, and drive long-term value for shareholders.” The SOL purchase follows the first closing under the Company’s $100 million facility. FTEL intends to make additional...